Targeting Bioreductive Drugs to Tumours: Is It Necessary to Manipulate Blood Flow
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 60 (1-2) , 231-236
- https://doi.org/10.1080/09553009114551911
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- SR 4233: A tumor specific radiosensitizer active in fractionated radiation regimesRadiotherapy and Oncology, 1991
- Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Induction of Hypoxia in the KHT Sarcoma by Tumour Necrosis Factor and Flavone Acetic AcidInternational Journal of Radiation Biology, 1991
- Interleukin-1α-induced Tumour Pathophysiologies Can Be Exploited with Bioreductive Alkylating AgentsInternational Journal of Radiation Biology, 1991
- The effects of single dose oral hydralazine on blood flow through human lung tumoursRadiotherapy and Oncology, 1990
- Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinomaBritish Journal of Cancer, 1989
- Keynote address: Hypoxic cell radiosensitizers: Where next?International Journal of Radiation Oncology*Biology*Physics, 1989
- The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: Evidence for therapeutic gainInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT)British Journal of Cancer, 1986
- Sensitizers and radiation dose fractionation: Results and interpretationsInternational Journal of Radiation Oncology*Biology*Physics, 1986